Healthcare Tech Outlook: Specials Magazine

What makes Workit Health’s evidence-based addiction recovery feel reachable for people facing opioid or alcohol use challenges? Addiction recovery begins the moment help feels reachable. For millions living with opioid or alcohol use disorders, the barriers of traditional treatment can make help feel out of reach. Workit Health bridges this accessibility gap and makes recovery possible by providing virtual, evidence-based treatment for substance use through a person-centered and holistic model of care. How is Workit Health’s integrated virtual care model structured to support stigma-free recovery? Workit’s defining differentiator is fast, stigma-free access to integrated support, where medical care, the guidance of behavioral health professionals, and peer connection work together from the privacy of one's own home. Shaped by a decade of expertise and a patients-as-designers philosophy, the evidence-based care is accessible through a secure, user-friendly application that helps members engage seamlessly. “Every person deserves a pathway to recovery that feels respectful, modern, and clinically sound. That's what we're building at Workit Health,” says Kate Katz, Chief Operating Officer.

When University Hospitals (UH) of Cleveland set out to improve transfusion management across its system, it faced a challenge shared by hospitals nationwide: transfusions are essential and lifesaving, but they are also widely overused, expensive, and sometimes harmful. Although UH saw major opportunities to reduce unnecessary transfusions, it struggled to find a product to impact clinician behavior or provide current, patient-specific insight to drive safer, evidence-based practice. Rather than accept this gap, UH built its own solution. The result was HemaLogiX™, a novel analytics platform that evaluates the appropriateness of every transfusion using patient-level variables and evidence-based guidelines. The platform proved so effective inside UH—cutting transfusions by 30–50 percent and generating $55 million in cumulative savings—that UH licensed the technology to a spin-out company, Hemaptics making the innovation available to health systems nationwide. “We started with a simple goal: give clinicians the kind of patient-specific insight that actually changes decisions,” says James Hill, MD, COO of UH Parma Medical Center and a founding clinical leader of the project. “Once we saw how powerfully HemaLogiX improved practice at UH, it became clear that other hospitals could benefit in the same way.” A Patient-Specific Approach Built for Clinical Reality Traditional transfusion tools rely on static metrics and generic thresholds that miss the complexity of real-world decision-making. By contrast, HemaLogiX integrates more than 80 patient specific data points and applies UH’s proprietary Transfusion Appropriateness Algorithm (TAA) to analyze each transfusion across all four major blood components. The platform delivers near-real-time insights, presenting information in a dynamic, intuitive dashboard that is updated daily. Clinicians, quality teams, and administrators can drill down to departments, providers, and individual encounters—with specific attribution ensuring transparency and trust. “Clinicians trust data when it reflects their exact patient,” says Dr. Hill. “HemaLogiX provides that level of context, so the feedback is relevant and actionable.”.